Fadi Agour

Zyprexa & Risperdal 2: The Breast Cancer Link That Could Ignite the Next Mass Tort

Fadi Agour, J.D. / By

The pharmaceutical litigation landscape has seen its share of blockbuster cases—from opioid multidistrict litigations to the ongoing Paraquat Parkinson’s claims. But a new California lawsuit (Brown v. Johnson & Johnson et al.) could revive two legacy antipsychotics with a startling twist: breast cancer allegations tied to prolactin elevation. The Plot Twist: From Gynecomastia to Oncology For …

Zyprexa & Risperdal 2: The Breast Cancer Link That Could Ignite the Next Mass Tort Read More »

Mass Torts in 2025: A Legal Landscape in Flux

Fadi Agour / By

As 2025 unfolds, the world of mass tort litigation shows no signs of slowing down. From pharmaceutical giants to tech behemoths, corporations across industries are facing an unprecedented wave of lawsuits that could reshape their futures. With judges issuing critical rulings, multidistrict litigation (MDL) panels consolidating cases, and bellwether trials on the horizon, the legal …

Mass Torts in 2025: A Legal Landscape in Flux Read More »

The PFAS Contamination Crisis: A Deep Dive into the Mass Tort Litigation and Its Implications

Fadi Agour / By

Per- and polyfluoroalkyl substances (PFAS), often referred to as “forever chemicals,” have become a focal point of environmental and public health concerns in the United States. These synthetic chemicals, used for their water, heat, and grease-resistant properties, are now at the center of one of the largest mass tort litigations in U.S. history. With thousands …

The PFAS Contamination Crisis: A Deep Dive into the Mass Tort Litigation and Its Implications Read More »

The Ultra-Processed Foods Lawsuit: A Must-Know Update for Mass Tort Lawyers

Fadi Agour / By

Ultra-processed foods (UPFs) have become a cornerstone of modern diets, but their convenience comes at a cost. As consumption of these foods has skyrocketed, so too have the alarming health complications linked to them, including obesity, diabetes, heart disease, and even certain cancers. This growing public health crisis has sparked a wave of litigation against …

The Ultra-Processed Foods Lawsuit: A Must-Know Update for Mass Tort Lawyers Read More »

Understanding the BioZorb Litigation: A Growing Legal Battle for Plaintiff Attorneys

Fadi Agour / By

What is BioZorb? The BioZorb litigation is shaping up to be one of the most significant legal challenges of 2025, presenting a unique opportunity for plaintiff attorneys nationwide. This case revolves around a medical device designed to aid breast cancer patients but has since been linked to serious complications, sparking widespread litigation. As the legal …

Understanding the BioZorb Litigation: A Growing Legal Battle for Plaintiff Attorneys Read More »

Ozempic Litigation Update

Mass Torts / By

Step into the forefront of mass tort litigation with Best Case Leads, where the burgeoning Ozempic litigation beckons the discerning attention of legal practitioners. As this dynamic landscape unfolds within the realm of Multidistrict Litigation (MDL) in the Eastern District of Pennsylvania, the focal point shifts sharply onto pharmaceutical titans Novo Nordisk and Eli Lilly, …

Ozempic Litigation Update Read More »

Navigating the Aftermath: Understanding Auto Accidents and Seeking Solutions

Mass Torts / By

By Sara Nour Auto accidents can be more than just unexpected collisions; they can be life-altering events that leave individuals grappling with physical, emotional, and financial challenges. In this comprehensive exploration, we will delve into the key aspects of auto accidents, shedding light on the aftermath, legal considerations, and avenues to seek solutions. Best Case …

Navigating the Aftermath: Understanding Auto Accidents and Seeking Solutions Read More »

Unlocking the Nuances of Paraquat Claims: A Comprehensive Guide

Mass Torts / By

Introduction: As we stand on the threshold of 2024, Paraquat claims are experiencing a resurgence of interest, and our commitment to navigating this intricate tort has been unwavering since 2021. In this extended article, we delve even deeper into the best practices employed at Best Case Leads, offering a comprehensive guide to not only address …

Unlocking the Nuances of Paraquat Claims: A Comprehensive Guide Read More »

Navigating Camp Lejeune Compensation: Beyond the Elective Option

Mass Torts / By

As the Camp Lejeune case progresses, the focus shifts to the qualifying conditions for compensation, prompting questions about the criteria. While federal guidelines provide a list of presumptive conditions for compensation, there is a growing awareness that non-presumed conditions, already attributed by the VA to Camp Lejeune water exposure, might yield significant awards. A pending …

Navigating Camp Lejeune Compensation: Beyond the Elective Option Read More »

Unveiling the Bard PowerPort Case: A Closer Look at the Emerging Mass Tort Scenario

Mass Torts / By

The mass tort landscape has been relatively calm in recent months, but a storm is brewing with the Bard PowerPort case gaining momentum. Let’s delve into the intricacies of this unfolding legal saga surrounding a cardiovascular catheter device that has stirred the interests of many, ourselves included. Understanding the Bard PowerPort: This implantable device, a …

Unveiling the Bard PowerPort Case: A Closer Look at the Emerging Mass Tort Scenario Read More »

The Buzz Surrounding Ozempic: Emerging Litigation Insights

Mass Torts / By

We recently had the opportunity to participate in an enlightening webinar courtesy of Mass Torts Made Perfect, focusing on the burgeoning Ozempic litigation that’s generating quite a buzz within legal circles. These webinars are invaluable for lawyers involved in mass torts, and the best part is they’re free. With over 250 attendees, the interest in …

The Buzz Surrounding Ozempic: Emerging Litigation Insights Read More »

Evolving Mass Tort Litigation: GLP-1 RA Weight Loss Drugs and the Emerging Gastroparesis Crisis

Mass Torts / By

Introduction In recent years, the use of GLP-1 receptor agonists (GLP-1 RAs) for weight loss has grown exponentially. These drugs, originally approved by the FDA for diabetes management, have been embraced by patients and physicians alike for their promising effects on shedding excess pounds. However, as their popularity surged, so did concerns over their safety …

Evolving Mass Tort Litigation: GLP-1 RA Weight Loss Drugs and the Emerging Gastroparesis Crisis Read More »

Best Case Leads